The Selective Serotonin 2A Receptor Antagonist Sarpogrelate Prevents Cardiac Hypertrophy and Systolic Dysfunction via Inhibition of the ERK1/2-GATA4 Signaling Pathway
Drug repositioning has recently emerged as a strategy for developing new treatments at low cost. In this study, we used a library of approved drugs to screen for compounds that suppress cardiomyocyte hypertrophy. We identified the antiplatelet drug sarpogrelate, a selective serotonin-2A (5-HT<sub...
Saved in:
Main Authors: | Kana Shimizu (Author), Yoichi Sunagawa (Author), Masafumi Funamoto (Author), Hiroki Honda (Author), Yasufumi Katanasaka (Author), Noriyuki Murai (Author), Yuto Kawase (Author), Yuta Hirako (Author), Takahiro Katagiri (Author), Harumi Yabe (Author), Satoshi Shimizu (Author), Nurmila Sari (Author), Hiromichi Wada (Author), Koji Hasegawa (Author), Tatsuya Morimoto (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Metformin suppresses phenylephrine-induced hypertrophic responses by inhibiting p300-HAT activity in cardiomyocytes
by: Yoichi Sunagawa, et al.
Published: (2021) -
Optimal Dose-Setting Study of Curcumin for Improvement of Left Ventricular Systolic Function After Myocardial Infarction in Rats
by: Yoichi Sunagawa, et al.
Published: (2014) -
Curcumin and its demethoxy derivatives possess p300 HAT inhibitory activity and suppress hypertrophic responses in cardiomyocytes
by: Yoichi Sunagawa, et al.
Published: (2018) -
Pyrazole-Curcumin Suppresses Cardiomyocyte Hypertrophy by Disrupting the CDK9/CyclinT1 Complex
by: Masafumi Funamoto, et al.
Published: (2022) -
EFFECT OF SARPOGRELATE ON FISTULA PATENCY OF FOREARM ARTERIOVENOUS ANASTOMISIS IN UREMIC PATIENTS
by: Jun Yuto, et al.
Published: (2012)